This study is looking at how intravenous immunoglobulin (IVIG) affects people with severe gastrointestinal (GI) motility disorders, like gastroparesis, that haven't responded to other treatments. Some people with these conditions have an autoimmune problem affecting their GI tract, sometimes called autoimmune gastrointestinal neuropathies (GAIN) or autoimmune gastrointestinal dysmotility (AGID). This observational study will document how patients who receive IVIG respond to the treatment. You might be able to join if you are between 12 and 90 years old and have GI motor disorder symptoms that haven't improved with other therapies. The study will measure success by tracking changes in your total GI symptoms score over up to one year. The current recruitment status is unclear.

Study design

This is an observational study, meaning researchers will watch and record what happens to patients who receive IVIG. It plans to include 400 participants.

What's involved

You would have your GI symptoms documented using a standardized survey at the beginning of the study and again after at least one course of IVIG therapy.

Compensation

Not stated in the trial record.

Follow-up

Your GI symptoms will be measured from the start of the study up to one year later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.